At this time, would you consider pausing therapy—specifically signaling inhibitors and/or monoclonal antibodies—in patients with chronic lymphocytic leukemia?
Recorded April 24, 2020.
As a result of COVID-19, has your decision model for front-line therapy changed for patients with multiple myeloma who are either transplant-eligible or ineligible?
Recorded April 24, 2020.
Irene M. Ghobrial, MD, of Dana-Farber Cancer Institute, talks about PROMISE—her screening study for people at high-risk of developing precursor conditions of multiple myeloma—and how this and other trials have been altered in the wake of the pandemic, as well as what might be considered a silver lining to the crisis. Filmed March 30, 2020.
During the COVID-19 pandemic, do you suggest delaying upfront autologous transplant for patients with multiple myeloma?
Recorded April 24, 2020.
For patients with multiple myeloma who are currently on clinical trials, what are the most pressing issues as we fight COVID-19?
Recorded April 24, 2020.
How has the COVID-19 pandemic changed your approach to the selection of tyrosine kinase inhibitors for the treatment of patients with chronic myeloid leukemia?
Recorded April 24, 2020.
